Floatz logo

METRONIDAZOLE

Hematologic Malignancies

Hospital Universitari Vall d'Hebron Research InstituteSmall moleculePhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
73/ 100

Competitive context

50 Active assets in the Hematologic Malignancies cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 2BB
cc-5013
CellCentric Ltd.
Phase 4BB
Evomela
Thomas Jefferson University
Phase 2BB
Monomethyl Fumarate
National Cancer Institute (NCI)
Phase 2BB
TACROLIMUS
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

METRONIDAZOLE is also rated in:

Surgical Site InfectionDormant
BBB
Indicative ·
72 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
Surgery--ComplicationsDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →